8-异丙基-1H-嘌呤 | 18202-81-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 8-异丙基-1H-嘌呤
• 英文名称: 8-Isopropyl-purin
• 英文别名: 8-isopropyl-7(9)H-purine；8-Isopropyl-1H-purine；8-propan-2-yl-7H-purine
• CAS: 18202-81-8
• 化学式: C₈H₁₀N₄
• 分子量: 162.194
• InChiKey: HMOAZVUOEBMMER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY
  申请人：Masuda Koji

  公开号：US20120253040A1

  公开（公告）日：2012-10-04

  Disclosed is a compound which is useful as an endothelial lipase inhibitor. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is aromatic carbocycle or aromatic heterocycle, Z is —NR 5 —, —O— or —S—, R 5 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or the like, R 1 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like, R 2 and R 3 are each independently hydrogen, halogen, hydroxy or the like, R 4 is a group represented by the formula: —(CR 6 R 7 )n-R 8 , wherein R 6 and R 7 are each independently hydrogen, halogen, hydroxy or the like, n is an integer of 0 to 3, R 8 is carboxy, cyano, substituted or unsubstituted alkyl or the like, R x is halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like, m is an integer of 0 to 3.

  揭示了一种作为内皮酶抑制剂有用的化合物。 一种由下式表示的化合物： 其药学上可接受的盐，或其溶剂化合物， 其中 环A是芳香碳环或芳香杂环， Z是-NR 5 —，-O-或-S-， R 5 是氢，取代或未取代的烷基，取代或未取代的烯基，取代或未取代的炔基，取代或未取代的芳基或类似物， R 1 是氢，卤素，羟基，氰基，硝基，羧基，取代或未取代的烷基，取代或未取代的烯基或类似物， R 2 和R 3 各自独立地是氢，卤素，羟基或类似物， R 4 是由下式表示的基团：-(CR 6 R 7 )n-R 8 ， 其中R 6 和R 7 各自独立地是氢，卤素，羟基或类似物，n是0到3的整数，R 8 是羧基，氰基，取代或未取代的烷基或类似物， R x 是卤素，羟基，氰基，硝基，羧基，取代或未取代的烷基，取代或未取代的烯基或类似物， m是0到3的整数。
• Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy
  申请人：Moravcova Daniela

  公开号：US20050080097A1

  公开（公告）日：2005-04-14

  The invention relates to 3-, 5-, 7-trisubstituted pyrazolo[4,3-d]pyrimidines represented by the general formula I and pharmaceutically acceptable salts thereof, wherein R3 is an optionally substituted alkyl, cycloalkyl, cycloheteroalkyl, cycloalkyl alkyl, aryl or alkylaryl group; R5 is halogen, —NHNH 2 , —NHOH, NHCONH 2 , guanylo (NH—C(NH)NH 2 ) an optionally substituted C 1 -C 6 alkyl, alkenyl, alkinyl, C 3 -C 15 cycloalkyl, R f (C 3 -C 15 cycloalkyl), heterocycle, heteroalkyl, aryl, heteroaryl, arylalkyl, cycloheteroalkyl, cycloheteroalkyl alkyl, heteroarylalkyl group, the group —C(O)—R a , —C(O)NR b R c , —SO 3 R d , or —NHC(O)R e , wherein R a and R f are an optionally substituted C 1 -C 6 alkyl, alkenyl, or alkinyl group, R b , R c and R d are independently selected from the group consisting of H, optionally substituted C 1 -C 6 alkyl, alkenyl, or alkinyl group, and R e is a hydroxy, amino, alkoxy, alkylamino, optionally substituted C 1 -C 6 alkyl, alkenyl or alkinyl group; or the group —X—R 5′ , wherein X is —NH—, —O—, —S— or —N(alkyl)- and R 5 ′ is hydrogen, an optionally substituted C 1 -C 6 alkyl, alkenyl, alkinyl, C 3 -C 15 cycloalkyl, Rf(C 3 -C 15 cycloalkyl), aryl, heterocycle, hetero C 1 -C 6 alkyl, arylalkyl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl alkyl, or heteroarylalkyl group, the group —C(O)—R a , —C(O)NR b R c , —SO 3 R d , or —NHC(O)R e , wherein R a , R b , R c , R d , R e and R f have the above meaning, and R7 is halogen, —NHNH 2 , NHOH, NHCONH 2 , guanylo (NH—C(NH)NH 2 ) or the group —X—R 7′ , wherein X has the above meaning and the meaning of R 7′ is as defined for R 5′ .

  本发明涉及一种由通式I表示的3-，5-，7-三取代吡唑并[4,3-d]嘧啶及其药学上可接受的盐，其中R3是可选取代的烷基，环烷基，环杂烷基，环烷基烷基，芳基或烷基芳基基团；R5是卤素，—NHNH2，—NHOH，NHCONH2，鸟苷基（NH—C(NH)NH2）可选取代的C1-C6烷基，烯基，炔基，C3-C15环烷基，Rf（C3-C15环烷基），杂环，杂烷基，芳基，杂芳基，芳基烷基，环杂烷基，环杂烷基烷基，杂芳基烷基基团，基团—C(O)—Ra，—C(O)NRbRc，—SO3Rd，或—NHC(O)Re，其中Ra和Rf是可选取代的C1-C6烷基，烯基或炔基，Rb，Rc和Rd是独立选择自H，可选取代的C1-C6烷基，烯基或炔基，Re是羟基，氨基，烷氧基，烷基氨基，可选取代的C1-C6烷基，烯基或炔基；或基团—X—R5′，其中X是—NH—，—O—，—S—或—N（烷基）-，R5′是氢，可选取代的C1-C6烷基，烯基，炔基，C3-C15环烷基，Rf（C3-C15环烷基），芳基，杂环，杂C1-C6烷基，芳基烷基，杂芳基，环杂烷基，环杂烷基烷基，或杂芳基烷基基团，基团—C(O)—Ra，—C(O)NRbRc，—SO3Rd，或—NHC(O)Re，其中Ra，Rb，Rc，Rd，Re和Rf具有上述含义，R7是卤素，—NHNH2，NHOH，NHCONH2，鸟苷基（NH—C(NH)NH2）或基团—X—R7′，其中X具有上述含义，R7′的含义如R5′所定义。
• Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha
  申请人：Lum T. Robert

  公开号：US20050080261A1

  公开（公告）日：2005-04-14

  Compounds of the following formula are provided: In the Formula (I), R 1 is —X—R 1 ′; in which R 1 ′ is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl, and X is —NH—. R 2 is lower alkyl optionally substituted with one, two or three groups chosen from hydroxy, lower alkoxy, and halogen. And R 3 is —NR 4 R 5 ; in which R 4 is hydrogen and R 5 is lower alkyl substituted with amino; or (ii) R 4 and R 5 are both lower alkyl optionally substituted with one, two or three groups chosen from hydroxy and amino. It is to be understood that R 1 ′ is not cyclohexylmethyl, phenyl, substituted phenyl, benzyl, phenylethyl, or m-hydroxybenzyl. The compounds inhibit CDK-2 activity and are useful for treating disorders characterized by undesirable cell proliferation.

  提供以下公式的化合物：在公式（I）中，R1为—X—R1′；其中R1′为可选择取代的低烷基、可选择取代的芳基、可选择取代的杂芳基或可选择取代的杂环烷基，X为—NH—。R2为低烷基，可选择取代一个、两个或三个羟基、低烷氧基或卤素基。R3为—NR4R5；其中R4为氢，R5为取代氨基的低烷基；或（ii）R4和R5均为低烷基，可选择取代一个、两个或三个羟基和氨基。应理解R1′不是环己基甲基、苯基、取代苯基、苄基、苯乙基或间羟基苄基。这些化合物能够抑制CDK-2活性，并用于治疗具有不良细胞增殖特征的疾病。
• Purine inhibitors of cyclin dependent kinase 2 & IkappaBalpha
  申请人：CV Therapeutics, Inc.

  公开号：US20020032327A1

  公开（公告）日：2002-03-14

  A 2,6,9-trisubstituted purine composition that is useful for inhibiting cell proliferative disorders and as an antifungal agent.

  一种2,6,9-三取代嘌呤组合物，可用于抑制细胞增殖性疾病和作为抗真菌剂。